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Understanding human immunodeficiency virus type 1 (HIV-1) transmission is central to developing effective prevention strategies,
including a vaccine. We compared phenotypic and genetic variation in HIV-1 env genes from subjects in acute/early infection and sub-
jects with chronic infections in the context of subtype C heterosexual transmission. We found that the transmitted viruses all used
CCR5 and required high levels of CD4 to infect target cells, suggesting selection for replication in T cells and not macrophages after
transmission. In addition, the transmitted viruses were more likely to use a maraviroc-sensitive conformation of CCR5, perhaps identi-
fying a feature of the target T cell. We confirmed an earlier observation that the transmitted viruses were, on average, modestly under-
glycosylated relative to the viruses from chronically infected subjects. This difference was most pronounced in comparing the viruses
in acutely infected men to those in chronically infected women. These features of the transmitted virus point to selective pressures dur-
ing the transmission event. We did not observe a consistent difference either in heterologous neutralization sensitivity or in sensitivity
to soluble CD4 between the two groups, suggesting similar conformations between viruses from acute and chronic infection. However,
the presence or absence of glycosylation sites had differential effects on neutralization sensitivity for different antibodies. We suggest
that the occasional absence of glycosylation sites encoded in the conserved regions of env, further reduced in transmitted viruses, could
expose specific surface structures on the protein as antibody targets.
Sexual transmission of human immunodeficiency virus type 1(HIV-1) involves a genetic bottleneck (reviewed in references
1 and 2) that typically results in the acquisition of a single trans-
mitted/founder virus (3–8). The low transmission rates of HIV-1
are most consistent with infection by a single variant rather than
transmission of a larger population with differential outgrowth.
Understanding the biological determinants of the transmission
bottleneck is central to developing appropriate strategies to block
transmission either by vaccination or other interventions. Thus,
there continues to be an interest in characterizing the nature of the
transmitted virus as one source of information about the selective
pressures at work during transmission.
There are several reasons why there could be phenotypic dif-
ferences between the transmitted virus and viruses typically found
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in the blood of the donor. Such differences could arise if the virus
population in the donor’s genital tract is a distinct subset of the
virus in the donor (i.e., compartmentalization). In addition, phe-
notypic differences may arise due to selection at any of several
steps in the transmission process. First, selection may favor viruses
that are better able to cross the mucosal surface to reach an initial
target cell. Second, selection at the site of transmission may favor
viruses capable of infecting available target cells, such as T cells or
macrophages, or interacting with dendritic cells (DCs). Third, se-
lection may favor viruses capable of rapid replication in the initial
target cell. Fourth, selection may favor viruses whose phenotypes
direct them to specific sites, such as the gut-associated lymphoid
tissue, where the amount of virus is greatly amplified early after
infection. One or more of these features of transmission may im-
pact the biological properties of the virus that initiates infection.
The nature of the transmitted virus has been examined in sev-
eral settings. Initially, these variants were thought to be macro-
phage-tropic (9, 10). While the transmitted virus is predomi-
nantly an R5 virus (8, 10–15), more recent evidence indicates that
macrophage tropism is not required for transmission, and in sev-
eral studies, there were no examples of transmission of a virus that
could efficiently replicate in macrophages (12, 16–18) or infect
cells with low levels of CD4 (a surrogate for macrophage tropism)
(11, 13).
Other features of the transmitted variant have also been exam-
ined. In several studies, there has been consistent observation of
reduced length of the variable regions in the Env protein and/or
reduced N-linked glycosylation density of the Env protein, fea-
tures reported for subtypes C, A, and D HIV-1 (4, 19, 20) but less
clear for subtype B HIV-1 (19, 21, 22). An analysis of a large data
set of subtype B env sequences revealed in the transmitted viruses
selection for a basic amino acid at position 12 in the Env leader
sequence that increases Env density on virions and underrepre-
sentation of a glycosylation site at codon 413 (23, 24), although
this site is typically not present in subtype C HIV-1. It has been
reported that the reduced glycosylation of the Env protein of
transmitted viruses enhances binding to 47 integrin associated
with CD4 T cells found in gut-associated lymphoid tissue and
impacts Env conformation and the interaction with CD4 (25),
although this relationship was not detected in a larger sampling of
transmitted viruses (13). Other reported features of the transmit-
ted virus are increased neutralization sensitivity to autologous do-
nor antibodies but not heterologous antibodies for subtype C
HIV-1 (4) and increased sensitivity to antibodies that bind to the
CD4 binding site, suggesting an altered Env conformation, for
subtype B HIV-1 (15), although this was not seen for subtype C
HIV-1 (13).
N-linked glycosylation plays an important role in the biology
of the viral Env protein (reviewed in reference 26). There are ap-
proximately 30 glycosylation sites encoded in the extracellular do-
main of the Env protein, with roughly two-thirds encoded in the
relatively conserved domains of Env and one-third in the highly
variable regions (27, 28). These sites are present at high frequency,
such that carbohydrate accounts for 50% of the protein weight
(29). After processing, the added glycan is largely left in a high-
mannose configuration (30). An initial mutational analysis of en-
coded N-linked glycosylation sites showed that they were largely
not essential for viral replication, leading to the suggestion that
their primary role was immune evasion (31). Subsequent studies
have examined the role of glycosylation in neutralization sensitiv-
ity and the evolution of neutralization resistance (32–50), sup-
porting the hypothesis that the carbohydrate side chains function
as a glycan shield protecting the surface of the Env protein from
host antibodies (47). However, there is great variability in the
number of encoded glycosylation sites in the env gene, pointing to
a dynamic system where sites are being selected for or against to
create the observed diverse viral population.
Because of the extreme heterogeneity of the HIV-1 Env pro-
tein, it is important that concepts concerning HIV-1 transmission
be formulated based on large sample sizes. Here, we compared the
sequences of a large number of viral Env proteins from acute/early
infections (n  68) to Env proteins present in contemporaneous
chronic infections (n  62) in the setting of heterosexual trans-
mission of subtype C HIV-1. We found that the Env protein of the
transmitted virus was 5% underglycosylated on average compared
to Env proteins in chronically infected subjects, with the virus
found in acutely infected men being 7% underglycosylated rela-
tive to the virus found in chronically infected women. The differ-
ence between acutely infected women and chronically infected
men was much less pronounced, suggesting that underglycosyla-
tion is principally a feature of female-to-male transmission and
not a general feature of all transmission types. A subset of the
sequences analyzed were cloned into an expression vector to assess
the phenotypic characteristics of the Env protein in pseudotyped
virus assays. The transmitted viruses were not differentially sensi-
tive to heterologous neutralizing antibodies (with one exception),
consistent with the transmitted virus having a conformation sim-
ilar to that of the virus in chronically infected subjects with respect
to antibody sensitivity. In addition, we found, using a more quan-
titative assay for CD4 dependence in entry, that the transmitted
viruses required high levels of CD4 to infect cells, consistent with
an activated CD4 T cell and not a macrophage being the initial
target cell for replication after transmission. Both types of viruses
could use a form of CCR5 that was inhibited by maraviroc, a
CCR5 antagonist. However, only a fraction of the transmitted
viruses were able to utilize an alternative conformation of CCR5
that was insensitive to maraviroc, while a majority of viruses from
chronic infections were able to use this conformation. Collec-
tively, these differences suggest selective pressures at work during
transmission. In addition, the underglycosylation of the transmit-
ted/founder virus highlights the fact that the presence of many of
the glycosylation sites is variable. We propose that these glycosy-
lation sites can be grouped by their proximity to specific surface
structures of the Env protein and that the absence of glycosylation
sites may make the virus vulnerable to antibodies targeting these
protein surface structures.
(These results were presented in part at the March 2012 CROI
Meeting.)
MATERIALS AND METHODS
Cohort description. Plasma samples from 68 subjects identified as having
acute/early subtype C HIV-1 infection were previously described (3) (the
previous study included one acute-to-acute transmission pair, one of
which has been omitted from this study to avoid overrepresentation of
this sequence in the analysis). This group included 27 subjects in Fiebig
stages (51) I to III, 32 in stages IV and V, and 8 in stage VI. One participant
was indicated as stage V or VI. All subjects were identified and enrolled in
the CHAVI 001 or CAPRISA 002 acute infection study. Subjects who did
not have acute HIV-1 infection were identified as chronics if a fully posi-
tive HIV-1 Western blot result was obtained (p31). A total of 62 subjects
were identified with chronic HIV-1 infection from cross-sectional cohorts
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in Malawi and South Africa. Subjects with advanced HIV-1 disease
(CD4 T cell counts 200 cells/ml) were excluded. All samples were
collected with written informed consent, and all protocols were approved
by institutional review boards at the collection sites.
Isolation of viral RNA and SGA. Plasma was collected in the presence
of either acid-citrate-dextrose (ACD) or EDTA. HIV-1 viral loads from
blood plasma were determined by using Abbott RealTime assays. An ali-
quot of between 140 and 200 l was extracted using the Qiagen QIAmp
viral RNA minikit, with the final eluted volume being 50 l. For each
sample, approximately 10,000 viral RNA copies were reverse transcribed
in a 100-l reaction mixture that included SuperScript III reverse trans-
criptase (Invitrogen) and either the OFM-19 primer or oligo(dT) as pre-
viously described (3, 8, 52). The cDNA product was then serially diluted
and used in a nested PCR amplification strategy to amplify the viral env
gene using primers as described previously (3, 8, 52). Between 20 and 30
amplicons were generated at a dilution where approximately 30% of the
PCR amplifications gave an appropriate product. The amplicons were
sequenced bidirectionally and further screened to ensure that a single
template gave rise to each amplicon by eliminating sequences that showed
evidence of mixtures. Single-genome amplification (SGA)-derived env
amplicons with frameshift mutations that resulted in premature stop
codons were excluded.
Analysis of viral sequences. DNA sequence alignments were per-
formed using ClustalW (53) and hand edited. Phylogenetic trees were
generated using neighbor-joining methods in MEGA 4.0 (54). Phyloge-
netic trees and highlighter plots (www.hiv.lanl.gov) were used to deter-
mine the number of transmitted variants in subjects with acute infection.
The consensus sequence was determined for all subjects with acute infec-
tion using Consensus Maker (www.hiv.lanl.gov), and the consensus se-
quences in subjects with multiple transmitted variants were determined
within each clade. The number of encoded N-linked glycosylation sites
was determined using N-Glycosite (www.hiv.lanl.gov) for the ectodo-
main of gp160. To determine the frequency of glycosylation site conser-
vation, the variable-length regions of V1/V2 and V4/V5 were deleted from
the sequences, which were then realigned to allow a tally at each site.
Glycosylation sites are numbered according to HXB2.
Cloning of env genes and generation of pseudotyped virus. Full-
length rev-vpu-env cassettes were cloned into pcDNA 3.1 from the direc-
tional Topo expression kit (Invitrogen) as previously described (8, 52, 55).
The entire insert of the molecular clones was sequenced to ensure a match
with the transmitted variant in subjects with acute infection. In subjects
with chronic infection, a representative SGA-derived env amplicon was
selected from the predominant clade for cloning. All inserts were con-
firmed to match the amplicon sequence. A subset of env genes were mu-
tagenized by plasmid resynthesis using overlapping PCR primers contain-
ing the mutation of interest.
Viral stocks for neutralization assays were generated by transfecting
293T cells with a subtype C backbone vector (ZM247Fv1deltaenv) and the
HIV-1 env clones as previously described (56). Viruses were harvested 48
h after transfection, filtered through a 0.45-mm filter, and frozen in ali-
quots. Viral titers were determined by measuring luciferase expression
after infecting TZM-bl cells (catalog no. 8129; NIH AIDS Research and
Reference Reagent program). Viruses used in Affinofile entry assays were
produced identically except that the 293T cells were cotransfected with
env clones and the pNL4-3.lucRE plasmid.
Virus neutralization assay. Single-round neutralizing antibody as-
says were performed as previously described (56). Neutralization of virus
was quantified by the reduction in luciferase reporter gene expression
after infection of the TZM-bl reporter cell line. Neutralization titers were
reported as the antibody concentrations for monoclonal antibodies and
the polyclonal sera which were used as purified IgG fractions, with the
value that gave a 50% reduction in relative luminescence units (RLU)
being reported. These values were interpolated using 5 parameter curve-
fitting.
Affinofile cell entry assay. In order to quantify virus entry at high
versus low concentrations of CD4 on the cell surface, Affinofile cells (57)
were seeded into 96-well plates. Twenty-four hours later, ponasterone A
and doxycycline were added at concentrations that induced the desired
CD4 (low, 2,000 antibody binding sites [ABS]/cell; high, 70,000 ABS/
cell) and CCR5 levels (high, 30,000 ABS/cell). Twenty hours later, we
removed the drugs, quantified receptor densities with flow cytometry (an-
ti-CD4 monoclonal antibody RPA-T4 and anti-CCR5 monoclonal anti-
body 2D7), and infected the cells with pseudotyped viruses using spinocu-
lation (58). Forty-eight hours after spinoculation, the cells were lysed and
luciferase activity in the cell lysate was measured.
Analyses. Standard statistical analyses were performed using R statis-
tical software (version 2.14.1). Model fitting of infection data was per-
formed using the R statistical package (drc) designed to analyze dose
response models (drm). These analyses fit a four-parameter, log-logistic
model to the data.
Direct statistical comparison of genetic data can be biased by phy-
logenetic relatedness among the data. To avoid biases caused by closely
related sequences in comparing the glycosylation site density between
sequences from acutely and chronically infected subjects, we used the
difference between glycosylation site density of an extant sequence and
its most recent ancestor. Comparison of extant sequences to the most
recent common ancestors to correct for phylogenetic bias in statistical
comparisons of genetic variables has been adopted successfully in the
past, e.g., by Bhattacharya et al. (59). In cases where more than one
sequence was present from the same subject, in addition to the direct
most-recent common ancestor, we used the most closely related se-
quence from another subject to account for phylogenetic signals in the
data and used a statistical modeling approach to account for similari-
ties (due both to shared ancestry and shared intrasubject environ-
ment) between sequences from the same subject. In all cases, the
counts of changes were divided by the total number of residues in
the sequence to calculate the change in glycosylation site density since
the most recent ancestor. This was used as the variable for nonpara-
metric comparisons between sequences from acutely and chronically
infected groups.
The glycosylation site count of the most-recent ancestor was estimated
in two main ways. First, the most recent ancestor amino acid sequence was
reconstructed using GASP (gapped ancestral sequence prediction for pro-
teins) (60), which considers the possibility of indels occurring between an
ancestor and its descendants and is thus appropriate for identifying gains
and losses of glycosylation sites. GASP determines ancestral states based
on the most-probable residue (including gaps) obtained by considering
residues at the descendant nodes, branch lengths, and employment of the
PAM1 matrix of amino acid substitutions. We inferred and counted mu-
tations that had occurred at the glycosylation sites of each extant sequence
since evolution from the most-recent ancestor. Second, continuous values
for the glycosylation site density of the most-recent ancestor of each se-
quence were directly estimated using the ancestral character estimation
(ACE) function under the Analyses of Phylogenetics and Evolution pack-
age in R (61). The ancestry estimates in ACE were done using (i) phylo-
genetically independent contrasts (PIC) of ancestral values and (ii) gen-
eral least-squares (GLS), assuming Brownian motion of evolution along
the tree (62, 63). We used linear mixed-effects models to compare changes
in glycosylation site density between groups of subjects, considering the
subject as a random effect and including the country of origin, infection
stage, or both as covariates.
Nucleotide sequence accession numbers. The sequences obtained from
subjects with acute infection have been described previously (3). The se-
quences obtained from subjects with chronic infection have been submitted
to GenBank under accession numbers KC862610-KC863648, HM638963-
HM638965, HM638988-HM638989, HM638993-HM638994, HM638997-
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HM639202-HM639203, HM639078, HM639084, HM639096, HM639141,
HM639150, HM639168, HM639171, HM639173, HM639177, HM639180,
HM639192, and HM639197. The sequences of the plasmid env expression vec-
tors have been submitted to GenBank under accession numbers KC894073-
KC894138, and KC894383-KC894388.
RESULTS
Cohort characteristics and sequence generation. In this study,
we examined a large set of viral env genes from people in acute/
early infection with subtype C HIV-1 who were infected via a
heterosexual route. The HIV-1 env sequences from 68 acutely in-
fected subtype C subjects have been described previously (3).
Briefly, subjects were identified as being in acute infection by the
presence of viral-specific antibodies and viral RNA and were as-
signed to Fiebig stages I to VI (51). As a control group, we chose
contemporaneous seroprevalent cases (Table 1). This control/
chronic group is a surrogate for the real population of linked do-
nors, which were not available for this large cohort. Since the time
of infection was not known for the control group, we used the
inclusion criterion of a CD4 T cell count between 200 and 500
cells/l, with a total sample size of 62 subjects. Molecular clones
were made of the env consensus sequence from 34 acutely infected
subjects who were infected with a single variant. For comparison,
one env clone was made from each of 31 chronically infected sub-
jects. The env genes were cloned into a plasmid expression vector,
and these clones were used to complement an env viral genome
encoding a reporter gene to create pseudotyped virus. We also
used a set of 35 samples obtained from the South African Blood
Bank as a validation group for subjects in acute infection (viral
RNA positive/antibody negative). Viral RNA was extracted from
blood plasma for each subject, the RNA converted to cDNA, and
the cDNA used as the template in the template endpoint dilution
strategy, single-genome amplification (SGA), to generate ampli-
cons spanning the viral env gene. An average of 20 amplicons were
sequenced per sample.
The transmitted virus in heterosexual transmission requires
high levels of CD4 to enter cells. We used the pseudotyped viruses
to test infectivity on cells expressing a wide range of CD4 densities.
The ability to infect cells with low levels of surface CD4 is a feature
of viruses that are able to infect macrophages (64–67) and of the
Ba-L isolate, which was originally derived by culturing on macro-
phages (68). This phenotype of CD4 density dependence is con-
veniently measured using Affinofile cells, which have both CD4
and CCR5 under the control of inducible promoters (57). We
have recently shown that viruses produced from long-lived cells in
the central nervous system (CNS) have the capability to infect
Affinofile cells at the lowest CD4 levels, a property shared with the
Ba-L isolate, while viruses found in the blood generally do not,
suggesting that viruses with the ability to infect cells expressing
low levels of CD4 (e.g., macrophage/microglia) are not readily
found in the blood (69). Here, we used the titration of CD4 levels
on Affinofile cells as a much more reliable and quantitative assay
for the determination of CD4 dependence, rather than using mac-
rophages, which can vary significantly in the level of CD4 ex-
pressed in different cell preparations (unpublished data).
Entry assays were performed using pseudoviruses to infect Af-
finofile cells with CD4 levels titrated over a range from 1,780 an-
tibody binding sites (ABS)/cell (uninduced) to 63,498 ABS/cell
(fully induced) (Fig. 1A). Pseudoviruses were generated using env
genes cloned from subjects with acute infection and with chronic
infection and with two control clones: Ba-L and JR-CSF. Ba-L is
the prototypic macrophage-tropic clone, while JR-CSF is a proto-
typic R5 T cell-tropic clone (requiring high levels of CD4 to enter
a cell). All of the viruses from both the acute and chronic infec-
tions, as well as the R5 T cell-tropic clone JR-CSF, had dose-re-
sponse curves that went to very low levels of infectivity at the
lowest levels of CD4 tested and had concave curves that often did
not saturate at the highest levels of CD4. This was in contrast to the
macrophage-tropic Ba-L isolate, which retained approximately
20% infectivity at the lowest level of CD4 (the same as viruses in
the CSF produced from long-lived cells [69]) and had a convex
dose-response curve with respect to the CD4 concentration. This
indicated that all of the viruses, with the exception of Ba-L, re-
quired high levels of CD4 in order to infect. Finally, the four pa-
rameters (50% inhibitory concentration [IC50], slope, upper
limit, and lower limit) used to fit each dose-response curve (4-
parameter log-logistic) did not differ between the transmitted vi-
ruses and viruses from chronic infections, indicating that there
were no consistent differences in how transmitted viruses and
chronically infected controls used CD4. Based on the requirement
for high levels of CD4 to mediate entry, we conclude that the
transmitted viruses were selected for replication in activated T
cells and not macrophages. Similarly, in this set of chronically
infected subjects, we did not find evidence for any macrophage-
tropic viruses in the blood plasma.
The transmitted viruses preferentially use a maraviroc-sen-
sitive conformation of CCR5 to enter cells. We next examined
the coreceptor tropism of these pseudotyped viruses. First, all of
the pseudotyped viruses were sensitive to the CCR5 antagonist
TAK-779 and, with the exception of one clone from a chronic
infection (3011), all of the viruses were insensitive to the CXCR4
antagonist AMD3100. Thus, consistent with previous reports (8,
10–15), the transmitted viruses in this cohort all used CCR5 for
entry. In our assays, we have seen that reducing Affinofile expres-
sion of CCR5 to its lowest level only reduced HIV-1 infectivity by
approximately 50% (data not shown). To add more information
about the utilization of CCR5 by these two groups of viruses, we
carried out titration with maraviroc (another CCR5 antagonist) at
both high and low expression levels of CCR5 on the Affinofile cells
to assess the efficiency of CCR5 utilization. In the first experiment,
we induced maximum levels of CCR5, treated the Affinofile cells
with a wide range of maraviroc concentrations, and infected them
with the transmitted viruses and the viruses from chronic infec-
tion (Fig. 1B). We found no difference in the mean IC50s for the
transmitted viruses and the viruses from chronic infections. How-
TABLE 1 Cohort description
Characteristica
Value (no. of male/female subjects)
Acutely infected










Mean age 27.0 yr (30/38) 29.4 yr (17/38)
Mean CD4 T cell count/l 508 (21/20) 370 (20/40)
Mean plasma viral RNA load
(log10)
6.9 (30/38) 5.4 (19/32)
a Age, CD4 T cell count, and viral load not available for all subjects.
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ever, we noted that some of the viruses were not fully inhibited at
the highest concentrations of maraviroc and, in fact, had a plateau
of infectivity resistant to maraviroc (i.e., the lower limit of the
curve was greater than zero). When we compared the frequency of
viruses in each group with and without a plateau in infectivity of at
least 10% in the presence of maraviroc, we found a difference
between the transmitted viruses and the viruses from chronic in-
fection (Fig. 2A), i.e., in the presence of high levels of CCR5, a
greater fraction of the viruses from chronic infection had a plateau
of infectivity of at least 10%. We performed an additional experi-
ment using 34 of the viruses (13 transmitted and 21 chronic) that
represented a range of maraviroc sensitivities when CCR5 levels
were high. When this subset of viruses was used to infect Affinofile
cells expressing the lower uninduced levels of CCR5 in the pres-
ence of maraviroc (10 M) we found that none of these viruses
displayed any plateau and all were fully inhibited by high levels of
maraviroc (Fig. 2B). We interpret these results to indicate that
CCR5 can exist in at least two conformations when expressed at
high levels, a maraviroc-sensitive conformation and a maraviroc-
resistant conformation, and that the transmitted viruses dispro-
portionately use the maraviroc-sensitive conformation.
Our results are consistent with two potential mechanisms of
maraviroc resistance. Either CCR5 could exist in an alternative
conformation that maraviroc is unable to bind but that a subset of
viruses can use for entry, or CCR5 could exist in an alternative
conformation that maraviroc binds and a subset of viruses are able
to use this maraviroc-bound alternative conformation.
Comparison of encoded glycosylation sites in HIV-1 env
gene sequences from acutely infected and chronically infected
subjects. A previous study comparing 8 linked donor-recipient
pairs infected with subtype C HIV-1 showed differences in vari-
able loop length and N-linked glycosylation site count (Asn-X-
Ser/Thr) in the transmitted virus (4), an observation that was
confirmed in a cohort infected with subtype A HIV-1 (19) but was
less apparent in two cohorts infected with subtype B HIV-1 (21,
22). We examined the encoded N-linked glycosylation count in
this large sampling of unlinked acutely infected and chronically
infected subjects. In this analysis, we assume that all encoded gly-
cosylation sites in the Env protein ectodomain are utilized, as pre-
viously reported for recombinant gp120 (29).
We used the env consensus sequence as the representative of
the transmitted viruses in the 68 acutely infected subjects (n  87)
but included all of the sequences from the 62 chronically infected
subjects (n  1,111), since each person has significant intrasample
variation in glycosylation site count and the level of sampling for
each chronically infected subject was similar. Equivalent results
were obtained when single sequences were selected from each
chronically infected subject in an iterative way to create multiple
comparator groups (data not shown). Figure 3A shows the distri-
bution of glycosylation site counts in env sequences from the
acutely infected subjects compared to that in env sequences from
the chronically infected subjects. There was a statistically different
distribution, with Env proteins from the acutely infected subjects
having a mean glycosylation site count of 28.3, compared to a
mean of 29.8 for the chronically infected subjects (a 5% difference
in total glycosylation count number; Wilcoxon W  33,681, P 
0.01). Thus, consistent with previous reports for heterosexual
transmission (4, 19), we observed that transmission favors Env
proteins that are modestly underglycosylated.
Reduced glycosylation count encoded in the viral env gene is
a feature of acutely infected men. We considered the possibility
that underglycosylation of the virus in acutely infected subjects
was specifically associated with transmission from male to female
or female to male. To address this question, we compared the
glycosylation site counts encoded in the env genes of acutely in-
fected men and women to the glycosylation site counts for the
subsets of men and women in the chronically infected group, with
the chronically infected group serving as a surrogate for the actual
donors. As shown by the results in Figure 3B, the viral env genes
from acutely infected men encoded fewer glycosylation sites than
the env genes from chronically infected women. Similarly, when
we compared env genes from acutely infected women to those
from chronically infected men, we found that env genes from the
acute population encoded fewer glycosylation sites, but this dif-
FIG 1 High CD4 dependence and differential use of CCR5 conformers of Env proteins. Subtype C env clones derived from both acute (red) and chronic (blue)
infections were used to generate pseudotyped viruses carrying a luciferase reporter gene. (A) The resulting viruses were used to infect Affinofile cells expressing
10 levels of surface CD4 (1,780, 7,360, 2,7983, 36,320, 43,758, 45,508, 45,931, 57,165, 58,152, and 63,498 ABS/cell) and a single high level of CCR5 (31,990
ABS/cell). After 48 h of infection, the cells were lysed and luciferase levels measured as relative light units (RLU). The percentage of RLUs measured at each CD4
level relative to the RLUs for high-surface-CD4 infection for each of the viruses is plotted. Included are controls consisting of Ba-L, to demonstrate the phenotype
of a macrophage-tropic virus, and JR-CSF, to demonstrate the phenotype of a virus that requires high levels of CD4 to infect cells (R5 T cell-tropic). (B) Reporter
pseudoviruses were also used to infect Affinofile cells expressing high levels of CD4 (88,104 ABS/cell) and CCR5 (35,981 ABS/cell) in the presence of 10 levels of
the CCR5 antagonist maraviroc (0.0001, 0.002, 0.003, 0.006, 0.013, 0.025, 0.05, 0.1, 1, and 10 M). Five of the acute clones were also analyzed in reference 97. The
pseudotyped viruses interpreted to have a plateau of at least 10% infectivity at the highest maraviroc concentration have an asterisk by the subject code. The






















FIG 2 Transmission selects for viruses that use a maraviroc-sensitive confor-
mation of CCR5. (A) We infected Affinofile cells expressing high levels of
CCR5 with a panel of viruses (data taken from the experiments whose results
are shown in Fig. 1) and observed that, in the presence of high levels of mara-
viroc, a greater fraction of the viruses from chronic infections had a plateau of
infectivity of greater than 10% (Fisher’s exact test; odds ratio  0.23, P  0.01).
(B) In order to determine whether resistance to maraviroc is mediated by
CCR5 level, we infected Affinofile cells expressing low levels of CCR5 in the
presence of maraviroc (10 M) using a subset of the viruses described in the
legend to Figure 1 (13 from acute infections and 21 from chronic infections,
representing a range of sensitivities to maraviroc). All of these viruses were
completely sensitive to inhibition by maraviroc when CCR5 levels were re-
duced. An analysis of three of these acute viruses was included in reference 97.
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ference was much smaller and did not reach statistical significance
(Fig. 3C). The mean glycosylation count value for each of these
groups is summarized in Table 2.
We considered several sources of error in this analysis, espe-
cially given that the samples were collected from two different
countries (South Africa and Malawi) and there was a different
proportion of males (higher in Malawi) and females (higher in
South Africa) from each country. When we corrected for phylo-
genetic relatedness among the sequences (59, 60), the difference in
TABLE 2 Mean glycosylation site count in the encoded Env protein
Source of
samplesa
Mean no. of glycosylation sites (no. of subjects in group):
Acutely infected: Chronically infected:
Males Females Males Females
CHAVI 27.9 (30) 28.7 (38) 29.3 (20) 30.2 (42)
SABB 28.6 (15) 29.8 (20)
a CHAVI, cohort described in Table 1; SABB, HIV-1 RNA-positive/antibody-negative
samples were obtained from the South African National Blood Bank.
* 
**
FIG 3 env genes from acutely infected individuals encode fewer N-linked glycosylation sites. Amplicons of env genes were generated from acutely infected
subjects and chronically infected subjects and sequenced. Each transmitted virus was represented by a single sequence, while all sequences from the chronically
infected subjects were included in the analysis. The number of encoded N-linked glycosylation sites was determined for each sequence based on the appearance
of the motif encoding NXS/T. (A) env sequences derived from acutely infected subjects were compared to env sequences from chronically infected subjects and
were found to encode significantly fewer N-linked glycosylation sites than the env sequences from chronically infected patients (Wilcoxon rank sum; W 
33,681, P  2 	 106). (B) env sequences derived from acutely infected males encode fewer N-linked glycosylation sites than env sequences derived from
chronically infected females (Wilcoxon rank sum; W  8,547, P  5 	 106). (C) env sequences derived from acutely infected females do not encode a
significantly different number of N-linked glycosylation sites compared to env sequences derived from chronically infected males (Wilcoxon rank sum;
W  7,734, P  0.13). (D) The frequency of appearance of N-linked glycosylation sites encoded in the conserved domains of the env sequences (and
present in at least 50% of sequences) was determined separately for the two groups of env sequences and plotted for each position (HXB numbering).
Adjacent positions that encoded mutually exclusive sites were pooled and are indicated by two position numbers. At those positions where the transmitted
virus sequences encode N-linked glycosylation sites at a greater frequency, the histogram is oriented up. At those positions where the sequences from the
chronically infected subjects encode N-linked glycosylation sites at a greater frequency, the histogram is oriented down. The positions are placed over a
map of the Env protein to show their presence in either gp120 or gp41. Four positions showed a statistically significant difference in glycosylation count
between the two groups at a P value of 0.05 (Fisher’s exact test), and these are boxed and indicated with a single asterisk. One position, 442, showed a
difference at a P value of 0.0001 and is shown boxed and with a double asterisk.
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glycosylation levels between the transmitted viruses and the vi-
ruses in chronically infected subjects persisted. In addition, the
biggest part of this difference remained in the comparison of vi-
ruses from acutely infected males versus viruses from chronically
infected females. We were able to detect a difference in glycosyla-
tion count between viruses from chronically infected females in
South Africa versus Malawi, but the intracountry comparison of
viruses from acutely infected males and viruses from chronically
infected females in Malawi remained significant, and the same
comparison in South Africa approached significance in spite of the
small number of males in that portion of the cohort. Thus, overall,
the data showed a significant reduction in glycosylation count of
the viruses in acutely infected people and, specifically, in acutely
infected men even after considering confounding factors of phy-
logenetic relatedness and geographic isolation.
Given that the glycosylation count difference between these
groups was relatively small (with the greatest difference being a
mean of 27.9 versus 30.2, or about 7%, for the comparison of
acutely infected men with chronically infected women), we used a
second set of samples for independent validation that selection for
underglycosylated viruses was most pronounced in female-to-
male transmission. Sequences were generated from 35 subjects in
acute infection based on their identification as being viral-RNA
positive but antibody negative at the time of blood donation. The
subjects were black South African blood donors who were infected
with subtype C HIV-1 and presumed to have been infected via a
heterosexual mode. For this analysis, we compared acutely in-
fected men (n  15) to acutely infected women (n  20) and saw
a similar trend, with the men having, on average, underglycosy-
lated Env proteins (mean of 28.6) compared to the glycosylation
of Env for the women (mean of 29.8) (Table 2). The high variance
in glycosylation count precludes this comparison from reaching
statistical significance, but the direction of the trend is the same as
in our larger analysis.
Distribution of glycosylation sites across Env. We next asked
if the underglycosylated sites (i.e., the missing sites) were ran-
domly distributed across the Env protein or if specific sites were
responsible for the differences in the transmitted viruses. We first
carried out an alignment of the env genes to identify all conserved
glycosylation sites. Because of the difficulty of aligning the length-
variable regions V1/V2 and V4/V5, these were excised from the
alignment and simply represented by the count of the number of
glycosylation sites encoded within the variable regions for each
sequence. In a few instances, adjacent glycosylation sites within
the conserved regions were pooled if they occurred in a mutually
exclusive (i.e., overlapping) way among the sequences. Using this
alignment, we identified 22 sites in the ectodomain of Env (out-
side the V1/V2 and V4/V5 variable-length regions), where a gly-
cosylation site occurred in at least 50% of the sequences. Some of
the glycosylation sites were present in nearly 100% of the se-
quences (highly conserved), while the rest were present at fre-
quencies ranging down to 60 to 70% of sequences (moderately
conserved). On average, there were 8 to 10 glycosylation sites en-
coded in the variable regions, or about one-third of the total gly-
cosylation sites in Env.
The frequencies of each N-linked glycosylation site in the se-
quences generated from the acutely and chronically infected sub-
jects were compared (Fig. 3D). When the counts of glycosylation
sites within the variable regions were analyzed, we found that ap-
proximately 60% of the reduced glycosylation count signal of the
acutely infected subjects could be accounted for within the vari-
able regions, with just over half of the effect in V1/V2 and just
under half in V4/V5 (data not shown). Within the conserved re-
gions of the Env ectodomain, we identified 8 glycosylation sites
that were more common in the transmitted viruses and 14 sites
that were more common in viruses from chronically infected sub-
jects (Fig. 3D). Of these, only one position was statistically less
common in the viruses from the chronically infected subjects (po-
sition 356/358), and four positions (234, 442, 611, and 624/625,
with the latter two being in the gp41 ectodomain of Env) were
statistically less common in the acutely infected subjects. These
data indicate that Env proteins from acutely infected subjects are
underglycosylated in both the highly variable regions and the rel-
atively conserved regions.
The transmitted virus in heterosexual transmission is not
globally neutralization sensitive but can show selective sensitiv-
ity. We next tested the pseudotyped viruses for neutralization sen-
sitivities to a group of monoclonal antibodies (Fig. 4A) and to a
group of broadly neutralizing polyclonal sera (Fig. 4B). The vi-
ruses, pseudotyped with these subtype C Env proteins, were
largely resistant to b12, 2G12, and 2F5 (at the concentrations
tested), as previously noted for this subtype (70). Those viruses
with some sensitivity to 2F5 had substitutions at A662, S665, and
K667 within the known 2F5 epitope in the subtype C consensus
sequence. There was no significant difference in sensitivity to
4E10 between the viruses pseudotyped with Env proteins de-
rived from acute versus chronic infection. For subtype B
HIV-1, the acute/transmitted virus has been reported to be
either more sensitive (71) or more resistant to 4E10 (8). In
addition, there was no difference in the sensitivity to soluble
CD4 (sCD4), suggesting similar conformations of the Env pro-
teins with respect to their interaction with CD4 and an absence
of an open Env conformation associated with culture-adapted
viruses (72). Similarly, the CD4 binding site monoclonal anti-
bodies VRC01 and CH31 showed no difference in their ability
to neutralize acute and chronic viruses (Fig. 4A). Finally, the
monoclonal antibodies PG9, PG16, and CH01, which are di-
rected at the -sheet scaffold of the V1 and V2 loops, also did
not distinguish the viruses from acute infection and those from
chronic infection. It is worth noting that the IC50 titers for each
of the more-active antibodies ranged from 100- to 1,000-fold,
indicating profound differences in sensitivity to neutralization
even for these broadly neutralizing antibodies.
The pseudotyped viruses with the different Env proteins dis-
played different but measurable neutralization sensitivities to a set
of seven sera previously characterized as broadly neutralizing, as
well as to pooled sera from subjects infected with subtype B HIV-1
(HIV Ig) or subtype C HIV-1 (HIV Ig-C) (Fig. 4B). For most of the
sera, including the HIV Ig pools, there were no detectable dif-
ferences in the sensitivities of the viruses from acute infection
and the viruses from chronic infection. Only one serum, SA-
C26, neutralized Env proteins from acutely and chronically
infected individuals differently, with viruses pseudotyped with
chronically derived Env proteins being significantly more sen-
sitive to SA-C26 than those derived from acute infections (P 
0.04) (Fig. 4B). Thus, the determinants of neutralization
sensitivity to heterologous sera (i.e., protein sequence and con-
formation) are largely shared and do not appear to be differen-
tially selected during transmission, at least within the limits of
detection given the size of this study.
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The presence or absence of glycosylation sites can differen-
tially affect the potency of monoclonal antibodies and poly-
clonal sera. Given the large data set of Env protein sequences and
neutralization sensitivities, we explored the contribution of the
presence or absence of specific glycosylation sites in determining
the neutralization potencies for the different monoclonal and
polyclonal antibodies. We used a natural log transformation of the
neutralizing titers in a linear regression model to explore the po-
tential contribution of each of the 22 glycosylation sites within the
conserved regions of the Env ectodomain. Because viruses from
acute and chronic infections typically do not differ in their neu-
tralization sensitivities, we pooled all of the data from both sets of
viruses to enhance our statistical power to detect a correlation
between specific glycosylation sites and neutralization sensitivi-
ties. The results are shown in Figure 4C, with filled bars indicating
that the presence of a glycosylation site reduced sensitivity to the
antibody (escape) and open bars indicating enhanced sensitivity
to neutralization if the glycosylation site was present (either as part
of the epitope or through a conformational change). Several cor-
relations supported the validity of this approach. First, two of the
CD4 binding site monoclonal antibodies were negatively im-
pacted by the presence of the glycosylation sites near the CD4
binding site, at positions 276 and 386 for VRC01 and 386 for b12,
a glycosylation site known to affect b12 potency (36, 73); however,
we did not detect a signal for the other CD4 binding site antibody,
CH31. Second, the potency of PG9 was enhanced when a glycosy-
lation site was present at position 160, which is known to be part of
the PG9 epitope in the V1/V2 -sheet scaffold (74, 75). PG16,
which has specificity similar to that of PG9, also had enhanced
potency when a glycosylation site was present at position 160; in
addition, PG16 showed enhanced potency when position 197 was
glycosylated (also part of the V1/V2 -sheet scaffold), although
this association lost statistical significance after correction for
multiple comparisons (data not shown).
Given our ability to observe correlations for interactions that
are known to exist, we analyzed the data for new interactions. We
note that SA-C26, which showed more potency toward viruses
from chronic infection than from acute infection (Fig. 4B), was
more potent when there was a glycosylation site at position 616
(Fig. 4C), a site that is underrepresented in the acutely infected
viruses (Fig. 3D). Thus, the differential glycosylation at this site
between viruses from acute infection and chronic infection may
account for the differential activity of this polyclonal serum with
these two groups of viruses. The monoclonal antibody CH01,
which is thought to target the -sheet scaffold of the V1 and V2
loops (76), was more potent in the absence of a glycosylation site at
position 130. Sensitivity to soluble CD4 was complex, with glyco-
sylation at positions 160 and 197 around the V1/V2 -sheet scaf-
fold conferring increased resistance and the juxtaposed glycosyla-
tion sites at positions 611 and 616 in gp41 differentially affecting
sensitivity to sCD4. These differences may reflect the impact on
either protein conformation or ease of conformational change; a
similar pattern for these two glycosylation sites in gp41 was also
seen for the polyclonal antibodies SA-C26 and SA-C62. Finally,
glycosylation at position 230 was associated with reduced sensi-
tivity to the monoclonal antibodies PG16 and 4E10 and the poly-
clonal antibodies HIV Ig and SA-C26 by an unknown mechanism,
since the epitopes for PG16 and 4E10 are dispersed between gp120
and gp41 (77).
As one test of the validity of these correlations (beyond the
known relationships) we examined the role of glycosylation at
position 130 in neutralization by CH01. The initial report of
epitope mapping of monoclonal antibody CH01 suggested that
CH01 and PG9 bind overlapping epitopes (76). However, in this
large panel of viruses, we saw that the presence of an N-linked
glycan at site 130 made viruses more resistant to CH01 but did not
alter sensitivity to PG9. To further explore the relationship be-
tween glycosylation at position 130 and sensitivity to CH01, we
mutated a panel of 10 of these subtype C env clones to encode Env
proteins fully glycosylated at the moderately conserved sites. In
addition, we mutated each of the otherwise fully glycosylated
clones to remove the glycan motif at 130. We saw an increase in
neutralization in three viruses when the clone lacked only the 130
glycan, consistent with the pattern of neutralization observed in
the larger panel. Two of the fully glycosylated viruses became sen-
sitive to CH01 when a glycosylation site at 160 was added to the
FIG 4 Comparison of sensitivity to antibody neutralization. (A and B) Viruses pseudotyped with Env proteins derived from chronically infected (blue) or acutely
infected (red) subjects were exposed to differing amounts of the indicated monoclonal antibodies or soluble CD4 (sCD4) (A) or to differing amounts of the
indicated polyclonal sera (purified IgG fraction) (B). For each virus, the IC50 was determined and plotted. The antibody that has the largest difference in median
values (shown by horizontal bars) is boxed, and the associated P value indicated (Kruskal-Wallis test). (C) Analysis of variance was used to evaluate the linear
model that best describes the relationship between neutralization sensitivity to each antibody/serum and 22 N-linked glycosylation sites in gp120 and gp41.
Relationships that are significant after correcting for multiple comparisons are plotted (*, P  0.05; **, P  0.01).
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parent, consistent with the earlier mapping that highlighted
the importance of glycan 160 in neutralization by CH01 (76). The
remaining 5 viruses were resistant to neutralization by CH01 in all
cases. These results also emphasize the complexity of the interac-
tion between glycosylation sites in individual Env proteins and
neutralization by glycan-binding antibodies.
DISCUSSION
Understanding the selective pressures acting on the Env protein
during transmission informs our knowledge of the mechanism of
transmission and is essential to the development of prevention
strategies. Several previous studies have observed that the trans-
mitted virus is underglycosylated in an HIV-1 subtype C cohort
(4) and in an HIV-1 subtype A cohort (19), although this effect
was less apparent overall in a subtype B cohort (19, 21, 22), with
the exception of underrepresentation of a glycosylation site at po-
sition 413 (24). We have been able to confirm this observation of
reduced glycosylation of the transmitted virus in this large subtype
C cohort (Fig. 3A). Consistent with the underglycosylation of the
Env protein in the transmitted virus, the virus accumulates glyco-
sylation sites during the course of infection (70, 78, 79). Thus,
there appears to be a cycling of glycosylation sites, with a reduction
at the time of transmission and an accumulation of sites over time.
Based on our and other studies (4, 19), it is clear that viruses
with fewer glycosylation sites can have a transmission advantage
in certain settings, but the magnitude and mechanism of this ad-
vantage is unknown. We have estimated what the magnitude of
this advantage would have to be in order to transform the distri-
bution of glycosylation counts among viruses from chronically
infected subjects into the distribution seen in the transmitted vi-
ruses. We estimate that an increase in the probability of transmis-
sion of 20% for each lost glycosylation site could account for the
differences in these distributions (Fig. 3A). A persistent question
has been whether this transmission advantage is due to selection at
specific glycosylation sites or selection for an overall reduction in
glycan number. Our observation that two-thirds of the reduction
in glycosylation sites was associated with the variable regions of
Env indicates that the transmission advantage is likely not due to a
specific glycan but, rather, that transmission of subtype C HIV-1
in the context of heterosexual transmission favors viruses whose
Env proteins have overall fewer glycans.
The fact that subtypes differ in the extent to which they favor
transmission of underglycosylated viruses may provide insight
into the mechanism of this transmission advantage. We hypothe-
size that this difference between subtypes B and C is due to differ-
ences in their predominant modes of transmission. This sugges-
tion is supported by two observations. First, the subtype B HIV-1
epidemic is dominated by male-to-male transmission, and the
magnitude of the transmission advantage of reduced glycosylation
is much less apparent. In contrast, subtype C HIV-1 is predomi-
nantly heterosexually transmitted, and transmitted HIV-1 sub-
type C variants have a more pronounced reduction in glycan
number. Second, we show that female-to-male transmission is
associated with a larger reduction in glycosylation count than
male to female (Fig. 3). Together, this suggests that transmission
from females selects for underglycosylated viruses.
Transmission from females requires that the virus maintain
infectivity after being secreted into the cervicovaginal mucus. Hu-
mans make a protein that binds mannose, mannose binding lectin
(MBL), and this protein has been shown to be capable of neutral-
izing HIV-1 (80). It is possible that MBL in vaginal secretions traps
or neutralizes virus in a way that is enhanced by higher glycosyla-
tion density. This model is consistent with the recent observation
of a reduced glycosylation count in viruses transmitted intrapar-
tum but not intrauterine (81). Alternatively, differences in Lang-
erhans cells (LCs) in the male epithelium and the female epithe-
lium (such as the differences observed between skin and vaginal
LCs [82]) could result in either enhancement of trans-infection of
T cells by underglycosylated viruses or inhibition of trans-infec-
tion of T cells by viruses that bind surface lectins too tightly due to
higher levels of glycosylation.
It is now clear that transmission involves the infection of a cell
with high levels of CD4, which identifies CD4 T cells as the tar-
get. Studies of tissue at the site of infection in recently infected
macaques found that T cells were the predominant cell type in-
fected (83). Several studies of human cohorts have failed to find
examples of transmitted viruses that can efficiently enter macro-
phages (12, 16–18) or infect cells with low levels of CD4 (a surro-
gate for macrophage tropism) (11, 13). We have used a large sam-
ple size and a quantitative assay for CD4 dependence to show that
the viruses transmitted in heterosexual transmission require high
levels of CD4 for entry, i.e., the high levels found on activated T
cells and not on macrophages (Fig. 1A). Given the low levels of
CD4 on dendritic cells from the peripheral blood (84) or the gut
mucosa (85), it is unlikely that infection of DCs plays a role in the
transmission process. Finally, our failure to find viruses isolated
from the blood of chronically infected individuals that have the
ability to enter cells with low levels of CD4 indicates that the evo-
lution of macrophage-tropic virus is likely restricted to very spe-
cific circumstances, such as in the CNS, where we have been able
to show a link between the infection of a long-lived cell and the
presence of virus able to enter cells with low levels of CD4 (69, 86).
Thus, the transmitted virus, and most examples of HIV-1 found in
the blood, are appropriately called R5 T cell-tropic.
Transmitted viruses and viruses from chronic infections do not
differ in how their Env proteins interact with CD4. This is based
on two assays: inhibition by soluble CD4 (Fig. 4) and entry effi-
ciency as a function of CD4 density (Fig. 1A). Previous work sug-
gested that a property of transmitted viruses is high 47 integrin
binding and low binding of gp120 to a monomer of soluble CD4,
with the typical HIV-1 Env protein having the reverse property
(25). Similar to our results with subtype C HIV-1, no difference in
sensitivities to soluble CD4 has been seen for subtype B HIV-1 in
comparing acute/transmitted viruses and viruses from chronic
infection (8, 71), although a difference has been reported for neu-
tralization sensitivities to CD4 binding site antibodies for subtype
B (15) but not subtype C HIV-1 (13) (Fig. 4A). Thus, if there are
differences in the interaction with CD4, they are small and largely
assay specific. Similarly, a recent analysis of a panel of transmitted
viruses and viruses from chronic infection failed to confirm a role
for 47 binding as a specific feature of the transmitted virus (13).
Overall, we found no difference in neutralization sensitivities be-
tween viruses from acute versus chronic infection, with the excep-
tion of one polyclonal serum (Fig. 4B). Thus, we conclude that
there are not significant differences in either conformation or het-
erologous neutralization sensitivity that distinguish the transmit-
ted virus. The relationship between underglycosylation of the
transmitted virus and neutralization sensitivity is less clear. In 13
of the 18 examples where glycosylation alters neutralization sen-
sitivity, underglycosylation increases sensitivity to neutralization
Features of Transmitted HIV-1
July 2013 Volume 87 Number 13 jvi.asm.org 7227
(Fig. 4C), but connecting this pattern to transmission is difficult
given that underglycosylation of the transmitted virus is likely a
small signal in the background of high variability of both neutral-
ization sensitivity and overall glycosylation diversity.
Another feature of the transmitted virus phenotype is an in-
creased ability to use a maraviroc-sensitive conformation of
CCR5. G protein-coupled receptors (GPCRs) have extreme levels
of structural flexibility that allow them to bind many different
ligands and achieve ligand-specific conformations (reviewed in
reference 87). Epitope mapping studies have found that some an-
ti-CCR5 monoclonal antibodies recognize a greater fraction of the
total CCR5 molecules than other antibodies, thus suggesting that,
like other GPCRs, CCR5 exists in a number of conformations (88,
89). While the nature of CCR5 conformational variation has not
been extensively studied, it appears to be substantial on both cul-
tured (88, 89) and primary T cells (88) and could be generated by
a number of mechanisms, including posttranslational modifica-
tion (90, 91), the lipid environment (92), and ligand or G protein
binding (87). Furthermore, some CCR5 antagonist-resistant vi-
ruses have been shown to differ in their sensitivities to anti-CCR5
monoclonal antibodies, raising the possibility that HIV-1 can
evolve the ability to bind these alternative CCR5 conformations as
a resistance pathway (88). Similarly, resistance to maraviroc has
been shown to vary by cell line and by donor (93), consistent with
the idea that different cells can display different forms of CCR5.
Here, we show that viruses isolated from chronically infected
subjects are more often partially resistant to maraviroc than vi-
ruses isolated from acutely infected subjects. While 75% of the
viruses from chronic infections had the ability to use this alterna-
tive conformation, only about 40% of the transmitted/founder
viruses could use this conformation (Fig. 1B and 2). Because the
subjects used in this study were treatment naive, these innate re-
sistance levels reveal variation in how viruses interact with CCR5.
This interpretation implies that viruses from chronic infection are
more variable in how they interact with CCR5 and that they are
able either to infect using maraviroc-bound CCR5 or using a
CCR5 conformation that maraviroc is unable to bind. It is possible
that this diversity in the ability to use different CCR5 conforma-
tions is analogous to the evolution to use CXCR4 as a coreceptor
late in infection, possibly allowing the virus to grow in a different
subset of T cells. Several studies have shown that R5 viruses taken
from late in disease are more difficult to inhibit with agents that
bind to CCR5 (14, 94). Since the viruses from chronic infection
have an expanded CCR5 coreceptor usage capacity, it is difficult to
explain a selective pressure that would restrict this capacity in the
transmitted virus. Perhaps the expanded coreceptor capacity al-
lows the virus to infect a cell type that is on average less productive
for successful transmission. Alternatively, this expanded corecep-
tor capacity may be linked to some other feature of Env that is
important for transmission or to the level of glycosylation. We do
not know which form of CCR5 predominates on CD4 T cells,
although the therapeutic efficacy of maraviroc suggests that it is
largely the sensitive form (95). However, a recent failure of mara-
viroc to block rectal transmission of the simian-human immuno-
deficiency virus (SHIV) isolate 162p3 in macaques in the face of
high drug exposure (96) may suggest a role for this alternative
conformation in at least some settings. Parrish et al. (13) did not
observe a resistance plateau using a largely nonoverlapping set of
subtype C HIV-1 isolates, although this analysis was done using a
cell line (NP2/CD4/CCR5) that expresses a single, lower level of
CCR5. These investigators have recently repeated this experiment
based on the results reported in our manuscript and have con-
firmed the difference in transmitted viruses versus chronic viruses
(97).
The modest underglycosylation of transmitted viruses (Fig. 3)
emphasizes the fact that glycosylation is a dynamic state for
HIV-1, with some glycosylation sites in the highly variable loops
being poorly conserved and other sites in the conserved regions of
Env being moderately or highly conserved. There are a number of
examples, from this and previous studies, indicating that there is
an intimate relationship between glycosylation at specific sites in
Env and sensitivity or resistance to antibody neutralization. We
propose that a vaccine that targets structural epitopes underlying
multiple, variable glycosylation sites could neutralize a large frac-
tion of viruses.
There are several examples where inclusion of part of the car-
bohydrate structure into the epitope has resulted in an antibody
that has broad neutralizing capacity, such as the monoclonal an-
tibody 2G12 (98, 99), the monoclonal antibody PGT 128, which
shows a specificity for the presence of a glycan at position 332
(100), and the broadly neutralizing antibodies PG9 and PG16,
which include specific glycans in the V1/V2 -sheet scaffold as
part of the epitope (35, 74, 101). However, epitopes that include
carbohydrate must be the exception to what the virus experiences,
since selection maintains such a high glycosylation density as a
general strategy to avoid neutralization.
There is also evidence that glycosylation sites can confer resis-
tance to neutralization, as opposed to being the target of neutral-
ization. Changes in glycosylation within the variable loops repre-
sent an important path of escape from autologous neutralizing
antibodies (77). There are also examples where moderately con-
served glycans have been implicated in protecting specific features
of the Env protein surface. The glycan at position 386 is a major
determinant of sensitivity to the CD4 binding site antibody b12
(36, 73), and we were able to see this effect across our data set, as
well as a potency effect on the CD4 binding site antibody VRC01
by glycosylation at 386 and the spatially adjacent site 276 (Fig. 4C).
Similarly, the 2 helix can be an important target for neutraliza-
tion (42, 102), with one example where escape was mediated by
the addition of a glycan at position 339 (103). More recently,
Moore et al. (104) have observed escape from an autologous neu-
tralization response by the addition of a glycan at position 332,
which then conferred sensitivity to the glycan-dependent mono-
clonal antibody PGT 128. Given that glycans are typically present
in the conserved regions of Env (Fig. 3D), the antibodies that react
with the surface protein structures of Env otherwise covered by
these glycans would appear as largely autologous, i.e., of restricted
range in their neutralization properties. A more systematic ap-
proach is needed to determine the breadth of the neutralization
properties of antibodies to these surface structures among isolates
where the same glycan is missing.
If these moderately conserved glycans are viewed as masks for
the Env protein surface, then these carbohydrate side chains can
be grouped as protecting specific structures (Fig. 5). The glycans at
positions 262, 332, 442, and 446/448 are all placed such that they
could occlude the surface of the three-stranded -sheet 12/13/
22. The glycans at positions 276 and 386 are positioned to protect
the protein surface around the CD4 binding site. Similarly, a
group of glycans (positions 88, 230, 234, and 241) in the region
where gp120 and gp41 are thought to interact (105, 106) could
Ping et al.
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represent a distinct domain where glycans are occluding putative
neutralization epitopes. The glycan at position 337/339 sits on the
2 helix. The single glycans on loop C (position 289) and loop E
(position 356/358) could similarly occlude specific epitopes in
these loops. Finally, the newly described four-stranded -sheet
that provides a scaffold for the V1 and V2 surface loops is covered
with four glycans (positions 130, 156, 160, and 197) (74).
Given that these glycosylation sites are variably present, we
asked what the mean occupancy of these sites was collectively
among the transmitted viruses. As can be seen by the results in
Figure 5, 93% of the transmitted viruses are missing a glycan as-
sociated with at least one of these structures, and 74% have at least
one glycan missing from two or more separate structures. If these
moderately conserved glycosylation sites protect epitopes that can
be recognized by the host, then the absence of some of these gly-
cosylation sites in most isolates should make the virus sensitive to
antibodies targeted to these surface structures of Env. In much the
same way that the virus toggles between cytotoxic T lymphocyte
epitope escape mutations and reversion to wild-type sequence
(107–109), the virus may also toggle between exposing an other-
wise carbohydrate-occluded epitope in the absence of the selective
pressure of neutralizing antibodies to that site in a specific host
and retaining (or evolving anew) the glycosylation site when there
is a host response to that protein surface epitope. A vaccine ap-
proach that was able to elicit a response to these surface structures
could represent a combinatorial approach to neutralizing a large
majority of transmitted viruses, targeting the differing subsets of
structures exposed on different viruses, an approach that is al-
ready being explored for the CD4 binding site (110). This strategy
would take advantage of the variable presence of these glycosyla-
tion sites in the conserved domains of Env among the entire viral
population, an advantage that is enhanced by the further reduc-
tion in glycosylation of the transmitted virus.
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